Oral Valproate Sodium as an Alternative to Benzodiazepine in the Treatment of Catatonia- A Case Report

Authors

  • Jacob C. Maier The University of Toledo School of Medicine Author
  • Daniel Rapport, MD The University of Toledo Medical Center Author
  • Alex McCormick, DO Northcoast Behavioral Healthcare Author
  • Chandani Lewis, MD The University of Toledo Medical Center Author

DOI:

https://doi.org/10.46570/utjms.vol8-2020-450

Keywords:

catatonia, depakote, sodium valproate, schizophrenia

Abstract

Alternative therapies are necessary to treat catatonia in patients with comorbidities that are not amenable to therapy with benzodiazepines or ECT. This is a patient with schizophrenia with catatonic features and a history of polysubstance abuse. Consequently, he was not a candidate for treatment with benzodiazepines, so an alternative needed to be found. GABAergic medications have been used previously as alternatives to benzodiazepines and ECT. In this case we chose sodium valproate, due to its cross-reaction with GABAergic systems. There are five reported cases using sodium valproate. Three of which were treated with intravenous valproate, while the remaining two do not specify the route of administration. We present a case where oral sodium valproate was used successfully for both acute and long-term catatonic treatment. To our knowledge, no other report has looked at both acute and long-term treatment with sodium valproate. Oral sodium valproate can be considered for patients with substance use disorders like COPD, sleep apnea or myasthenia gravis in which benzodiazepines are contraindicated and where ECT is not an option for treatment.

Author Biographies

  • Jacob C. Maier, The University of Toledo School of Medicine

    3000 Arlington Ave.

    Toledo, OH 43614

  • Daniel Rapport, MD, The University of Toledo Medical Center

    Department of Psychiatry

    3000 Arlington Ave.

    Toledo, OH 43614

  • Alex McCormick, DO, Northcoast Behavioral Healthcare

    Northcoast Behavioral Healthcare

    1756 Sagamore Rd

    Northfield, OH 44067

  • Chandani Lewis, MD, The University of Toledo Medical Center

    Department of Psychiatry

    3000 Arlington Ave.

    Toledo, OH 43614

References

Kruger S & Braunig P (2001) Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 13(2):303-304.

Bowers R & Ajit SS (2007) Is there a role for valproic acid in the treatment of catatonia? J Neuropsychiatry Clin Neurosci 19(2):197-198.

Yoshida I, Monji A, Hashioka S, Ito M, & Kanba S (2005) Prophylactic effect of valproate in the treatment for siblings with catatonia: a case report. J Clin Psychopharmacol 25(5):504-505.

DelBello MP, Foster KD, & Strakowski SM (2000) Case report: treatment of catatonia in an adolescent male. J Adolesc Health 27(1):69-71.

Tandon R, et al. (2013) Catatonia in DSM-5. Schizophr Res 150(1):26-30.

White DA & Robins AH (2000) An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr 5(7):58-65.

Mann SC, et al. (1986) Lethal catatonia. Am J Psychiatry 143(11):1374-1381.

Mann SC, Caroff SN, Bleier HR, Antelo RE, & Un H (1990) Electroconvulsive Therapy of the Lethal Catatonia Syndrome. Convuls Ther 6(3):239-247.

Hawkins JM, Archer KJ, Strakowski SM, & Keck PE (1995) Somatic treatment of catatonia. Int J Psychiatry Med 25(4):345-369.

Sienaert P, Dhossche DM, Vancampfort D, De Hert M, & Gazdag G (2014) A clinical review of the treatment of catatonia. Front Psychiatry 5:181.

Rasmussen SA, Mazurek MF, & Rosebush PI (2016) Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry 6(4):391-398.

Luchini F, et al. (2015) Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World J Psychiatry 5(2):182-192.

Tunnicliff G (1999) Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 50(3):347-365.

Kerwin RW & Taberner PV (1981) The mechanism of action of sodium valproate. Gen Pharmacol 12(2):71-75.

Baldino F, Jr. & Geller HM (1981) Sodium valproate enhancement of gamma-aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity. J Pharmacol Exp Ther 217(2):445-450.

Perez-Esparza R, Onate-Cadena N, Ramirez-Bermudez J, & Espinola-Nadurille M (2018) Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia. Neurologist 23(2):51-52.

Downloads

Published

2021-02-24

Issue

Section

Case Reports

How to Cite

1.
Oral Valproate Sodium as an Alternative to Benzodiazepine in the Treatment of Catatonia- A Case Report. Translation. 2021;8. doi:10.46570/utjms.vol8-2020-450

Most read articles by the same author(s)